CA2393837A1 - Utilisation de la descloratadine pour le traitement de patients pediatriques souffrant de conditions inflammatoires et allergiques - Google Patents

Utilisation de la descloratadine pour le traitement de patients pediatriques souffrant de conditions inflammatoires et allergiques Download PDF

Info

Publication number
CA2393837A1
CA2393837A1 CA002393837A CA2393837A CA2393837A1 CA 2393837 A1 CA2393837 A1 CA 2393837A1 CA 002393837 A CA002393837 A CA 002393837A CA 2393837 A CA2393837 A CA 2393837A CA 2393837 A1 CA2393837 A1 CA 2393837A1
Authority
CA
Canada
Prior art keywords
desloratadine
study
subjects
pediatric
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393837A
Other languages
English (en)
Inventor
Melton B. Affrime
Christopher R. Banfield
Samir K. Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393837A1 publication Critical patent/CA2393837A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de la desloratadine pour la préparation d'un médicament permettant de traiter et/ou d'empêcher une affection inflammatoire et allergique de la peau des voies respiratoires supérieures et inférieures chez un enfant, et une composition pharmaceutique pour enfant, permettant d'y parvenir. Cette composition pharmaceutique comprend une quantité efficace de desloratadine et un excipient pharmaceutiquement acceptable.
CA002393837A 1999-12-21 2000-12-19 Utilisation de la descloratadine pour le traitement de patients pediatriques souffrant de conditions inflammatoires et allergiques Abandoned CA2393837A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17291199P 1999-12-21 1999-12-21
US60/172,911 1999-12-21
PCT/US2000/034418 WO2001045688A2 (fr) 1999-12-21 2000-12-19 Traitement destines a des affections inflammatoires et allergiques

Publications (1)

Publication Number Publication Date
CA2393837A1 true CA2393837A1 (fr) 2001-06-28

Family

ID=22629711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393837A Abandoned CA2393837A1 (fr) 1999-12-21 2000-12-19 Utilisation de la descloratadine pour le traitement de patients pediatriques souffrant de conditions inflammatoires et allergiques

Country Status (6)

Country Link
EP (1) EP1239859A2 (fr)
JP (1) JP2003518045A (fr)
AU (1) AU2277301A (fr)
CA (1) CA2393837A1 (fr)
MX (1) MXPA02006347A (fr)
WO (1) WO2001045688A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup

Also Published As

Publication number Publication date
WO2001045688A3 (fr) 2002-05-02
WO2001045688A2 (fr) 2001-06-28
AU2277301A (en) 2001-07-03
EP1239859A2 (fr) 2002-09-18
MXPA02006347A (es) 2002-12-13
JP2003518045A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
US7902208B2 (en) Treating allergic and inflammatory conditions
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
McClellan et al. Desloratadine
CA2393837A1 (fr) Utilisation de la descloratadine pour le traitement de patients pediatriques souffrant de conditions inflammatoires et allergiques
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
US20030004179A1 (en) Treating allergic and inflammatory conditions
US20040138247A1 (en) Use of desloratadine for treating allergic and inflammatory conditions
US20060154948A1 (en) Treating allergic and inflammatory conditions
US20050203105A1 (en) Composition and method for controlling alcohol-induced facial flushing in susceptible humans
AU2001247867B2 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
Tablets DESLORATADINE ALLERGY CONTROL
Wood-Baker et al. The time course of action of three differing doses of noberastine, a novel H1-receptor antagonist, on histamine-induced skin wheals and the relationship to plasma drug concentrations in normal human volunteers.
EP1666066A1 (fr) Medicament contre le syndrome de down
JP2004534820A (ja) 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬
AU2001247867A1 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
Kappos et al. Uses
Tennant et al. Use of difenoximide (SC-26100) for narcotic detoxification: a preliminary tolerance and efficacy study
Agent pms-LOPERAMIDE HYDROCHLORIDE SOLUTION
DOYLE et al. I3ritbsh Pharmacoloqgical
Hydrochloride et al. PrMYLAN-PIOGLITAZONE
Agent PrPIOGLITAZONE HCL
EP1214071A2 (fr) Traitement d'etats allergiques et inflammatoires
AU2002315357A1 (en) Antihistamines for the treatment of nasal congestion and nasal obstruction
Agent APOTEX INC. DATE OF REVISION: 150 Signet Drive July 31, 2019 Toronto, Ontario
AU2006201218A1 (en) Treating allergic and inflammatory conditions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead